Post-earnings recap
Reported
Thu, Apr 27, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a wider-than-expected loss per share, which was a positive surprise compared to analyst expectations. However, the lack of revenue figures and guidance contributed to a slight decline in the stock price by 0.4%. Investors may be concerned about the company's future revenue potential given the absence of specific guidance and the focus on clinical trials.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | +14.23% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of their clinical programs. They did not offer specific guidance for future revenue.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its ongoing clinical trials.